Navigation Links
Inovio Pharmaceuticals' DNA Vaccine for Foot-and-Mouth Disease Generates Protective Neutralizing Antibodies in Second Large-Animal Study
Date:6/30/2011

e death rates are generally low, the highly infectious nature of the virus has a profound negative economic impact, such as in the dairy industry where cattle may experience reduced milk production, poor growth and permanent hoof damage. An FMD outbreak typically leads to economic sanctions, including the loss of export markets, and can negatively impact tourism as restrictions are placed on the movement of people and animals. This was the case in the 2001 outbreak in the UK.

About Inovio Pharmaceuticals, Inc.

Inovio is developing a new generation of vaccines, called DNA vaccines, to treat and prevent cancers and infectious diseases. Its SynCon™ vaccines are designed to provide broad cross-strain protection against known as well as newly emergent strains of pathogens such as influenza. These vaccines, in combination with Inovio's proprietary electroporation delivery devices, have been shown to be safe and generate significant immune responses. Inovio clinical programs include three Phase II studies for vaccines treating cervical dysplasia/cancer, hepatitis C virus, and leukemia. Other clinical programs target influenza (preventive) and HIV (preventive and therapeutic). Inovio partners and collaborators include the University of Pennsylvania, Merck, ChronTech, National Cancer Institute, U.S. Military HIV Research Program, NIH, HIV Vaccines Trial Network, University of Southampton, and PATH Malaria Vaccine Initiative. More information is available at www.inovio.com.

This press release contains certain forward-looking statements relating to our business, including our plans to develop electroporation-based drug and gene delivery technologies and DNA vaccines and our capital resources. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials and product development progr
'/>"/>

SOURCE Inovio Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Inovio Pharmaceuticals Prostate Cancer DNA Vaccine Demonstrates Strong T Cell Responses in Monkeys; Company on Track for Phase I Clinical Trial
2. Inovio Pharmaceuticals Reports Long-Term Immune Responses from Therapeutic Cervical Dysplasia and Cancer DNA Vaccine
3. Inovio Pharmaceuticals Enters Phase II Clinical Trial with SynCon™ DNA Vaccine for Cervical Dysplasia Caused by HPV
4. Inovio Pharmaceuticals Foot-and-Mouth Disease DNA Vaccine Introduces Critical Advantages in Fight Against Most Serious Farm Animal Disease
5. Inovio Pharmaceuticals to Present at 13th Annual BIO CEO & Investor Conference
6. Oramed Pharmaceuticals Appoints Dr. Michael Berelowitz as Chairman of Scientific Advisory Board
7. Amylin Pharmaceuticals to Present Promising New Data on the Companys Diabetes Programs at ADA 2011
8. MKM Partners Hires Biotechnology/Specialty Pharmaceuticals Analyst
9. Anthera Pharmaceuticals Announces Proposed Public Offering of Common Stock
10. FDA Grants Fast Track Designation to Tioga Pharmaceuticals Asimadoline for the Treatment of Diarrhea-Predominant Irritable Bowel Syndrome
11. Questcor Pharmaceuticals to Present at the Jefferies Global Healthcare Conference on June 9, 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... November 2012, the European Union (EU) mandated use of the ... PSUR – responding to the increasing need to understand and ... in many regions, the main objectives of the PBRER are ... analysis of new or emerging information on the risks of ... the potential benefits of a drug; and , ...
(Date:8/18/2014)... 19, 2014 2014 Deep Research ... a professional and in-depth research report on the ... information, including its definition, classification, application, and ... This research covers the international market analysis, including ... analysis covering macroeconomic environment & economic situation analysis. ...
(Date:8/18/2014)... , Aug. 18, 2014   Sterne, Kessler, Goldstein ... in Washington, DC , announced today ... Partes Review (IPR) with the U.S. Patent and ... subsidiary of BioReference Laboratories, Inc. (Nasdaq: BRLI).  These IPR ... licensed by Myriad Genetics, Inc. These patents have been ...
(Date:8/18/2014)... 18, 2014 According to ... By Application (Municipal Wastewater Treatment and Industrial Wastewater ... Multi Tubular), By Configuration (Internal/Submerged and External/Sidestream), and ... MarketsandMarkets, The market for membrane bioreactor systems is ... at a CAGR of 15.28% between 2014 and ...
Breaking Biology Technology:Top Five Best Practices for Developing Your Periodic Benefit Risk Evaluation Report (PBRER), New Webinar Hosted by Xtalks 2Linalool Industry & Diphenylamine Market (Global, China) 2014 Analysis Now Available at DeepResearchReports.com 2Linalool Industry & Diphenylamine Market (Global, China) 2014 Analysis Now Available at DeepResearchReports.com 3Linalool Industry & Diphenylamine Market (Global, China) 2014 Analysis Now Available at DeepResearchReports.com 4Sterne Kessler Files 11 IPR Petitions On Behalf Of GeneDx, Inc., Subsidiary Of BioReference Laboratories, Inc. 2Sterne Kessler Files 11 IPR Petitions On Behalf Of GeneDx, Inc., Subsidiary Of BioReference Laboratories, Inc. 3Membrane Bioreactor Systems Market Worth $2,927 Million by 2019 2Membrane Bioreactor Systems Market Worth $2,927 Million by 2019 3
... Jan. 3 Thoratec,Corporation (Nasdaq: THOR ), ... said today that it will be participating in ... Gary Burbach, president and chief executive officer, ... 8:30 a.m., Pacific Standard Time (11:30,a.m., Eastern Standard ...
... and CLAREMONT, Calif., Jan. 3 /Xinhua-PRNewswire-FirstCall/ --,Kiwa ... successful,exhibition of its Fertilizer Products in Dingxing, ... representatives with large volume distribution,businesses in 7 ... the exhibition,and agreements were reached with local ...
... 3 /PRNewswire/-- Intercept Pharmaceuticals, Inc., a,clinical-stage biopharmaceutical ... fibrotic and metabolic diseases, today announced the,appointment ... created position of,Chief Scientific Officer. Dr. Adorini ... research and development, recently serving as Chief ...
Cached Biology Technology:Kiwa Bio-Tech Products Group Holds a Fertilizer Products Exhibition in Hebei 2Kiwa Bio-Tech Products Group Holds a Fertilizer Products Exhibition in Hebei 3Intercept Pharmaceuticals Names Dr. Luciano Adorini Chief Scientific Officer 2
(Date:8/20/2014)... and POINT ROBERTS, Washington , August 20, ... Key Role in Addressing Security Concerns in the Payment Industry? ... news source covering leading sectors including biometrics, issues commentary from ... Jason Peaslee , Managing Partner at Thrive Analytics, ... Gino Pereira , CEO of NXT-ID, Inc. (OTCBB: NXTD) ( ...
(Date:8/19/2014)... to decrease China,s increasing caesarean section rate, suggests a ... An International Journal of Obstetrics and Gynaecology (BJOG) . ... rates in the world. Of 16 million babies born ... exact rate is not known, the current Chinese language ... rates ranging from 36% to 58%. However, before the ...
(Date:8/19/2014)... in supermarkets to encourage healthier spending habits? A new ... very question by tracking the purchasing records in a ... rate the nutritional value of foods for sale. , ... Just, PhD, and Brian Wansink PhD, author of Slim ... 150 Hannaford Supermarkets in the Northeastern United States between ...
Breaking Biology News(10 mins):Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 2Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 3Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 4Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 5Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 6Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 7Is China's 50 percent cesarean section delivery rate too high? 2Is China's 50 percent cesarean section delivery rate too high? 3
... a virulent family of bacteria called Yersinia, a group ... These bacteria insert into their host cells proteins and ... things -- disrupting the cells' normal structure. One of ... Now, a study published by Rockefeller University researchers in ...
... tend to have a much lower quality of life when they ... in the latest issue of the UK-based Journal of Advanced Nursing. ... 1500g or less and compared them with a control group of ... when it came to physical, emotional, cognitive and social functions. , ...
... a little mean sometimes ?especially when there's a choice bit ... flies have shorter tempers than others. , Researchers in ... suite of genes that affect aggression in the fruit fly ... abnormal aggression in humans and other animals. , The ...
Cached Biology News:A wolf in sheep's clothing: Plague bacteria reveal one of their virulence tricks 2Very low birth weight linked to reduced quality of life in pre-school children 2Fruit fly aggression studies have relevance to humans, animals 2Fruit fly aggression studies have relevance to humans, animals 3
Request Info...
Agarose, low melting/gelling temperature, high MW separation (>1000 bp), 25 g. Suitable for enzymatic modifications. Nuclease-free.Gel point: 24-30 C, EEO (-mr): 300 gm/cm2. Category: Nucleotides &...
Request Info...
Request Info...
Biology Products: